Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

ryptogenic organizing pneumonia, as compared to none of the orBec(R)-treated patients (p = 0.04).

The investigators, led by Dr. Jason Chien, reviewed data from two previous randomized, double-blind, placebo-controlled Phase 2 and 3 clinical trials evaluating orBec(R), for the treatment of acute GI GVHD. Data from 120 patients (sixty patients treated with orBec(R), sixty placebo) were available for this retrospective analysis. Patients were enrolled in these studies at the Fred Hutchinson Cancer Research Center, where pulmonary function testing is done prospectively and all patients with pulmonary complications are evaluated with a standard protocol. The investigators also evaluated adverse event reports of infectious and non-infectious inflammation of the lung.

These observations by Dr. Chien and colleagues on the preservation of pulmonary function among patients receiving orBec(R) is consistent with findings from the Phase 3 randomized trial reported by Hockenbery et al. (A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109: 4557 - 4563, 2007).

"While these trials were not designed to look at pulmonary endpoints, these observations suggest that a metabolite of oral BDP may be having a beneficial anti-inflammatory effect in the lungs of hematopoietic cell transplant recipients," stated Jason W. Chien, MD, MS, Assistant Member, Clinical Research Division of the Fred Hutchinson Cancer Research Center. "There was convincing evidence of preservation of lung function and an absence of non-infectious pulmonary disease in those who had received oral BDP. The explanation for this benefit appears to be related to the delivery of a small amount of the potent metabolite, 17-beclomethasone monopropionate, from the intestinal mucosa to the pulmonary artery via the p
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... January 23, 2015 Portal Solutions , ... workplaces on Microsoft Office 365 and SharePoint platforms , ... Award program for being one of the region’s fastest-growing mid-sized ... employee growth. , “To be recognized a second year ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... 13 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on commercializing proprietary product candidates for the ... that Evan M. Levine,ADVENTRX,s chief executive officer, ... Fifth Annual Growth Conference on Wednesday,September 19th, ...
... ... to inhibit ... 13, 9:45 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., Sept. 13 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ...
... VANCOUVER, Sept. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... today that it received a,favourable decision from ... an attempt by Johnson & Johnson,s subsidiary, ... Zealand Patent 523799, which,pertains to compositions comprising ...
Cached Biology Technology:ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 3Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 4
(Date:12/17/2014)... 2014 The Defense Logistics Agency is insourcing its ... counterfeit microcircuits from entering into its supply chain. ... anti-counterfeit initiative dubbed DNA marking. The capability will validate ... throughout the supply chain. The new quality control measures ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/17/2014)... is fundamentally transforming the travel experience and nowhere is ... past decade, ePassports, biometric readers, and secure document scanners ... control via eGates and Automated Passport Control (APC) Kiosks ... borders across the globe. According to ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... in the international conservation journal Oryx ... reintroduction of captive lions do little to further the conservation ... Online, on July 31, ,Walking with lions: Why there is ... species restoration, was authored by a blue-ribbon panel of lion ...
... cancer from one tissue to another may one day be ... print issue of The FASEB Journal ( http://www.fasebj.org ... on fruit flies) increases the "stickiness" that causes cells, including ... slows their movement throughout the body. "The study of ...
... the body are injured at their farthest reaches, coordinating the ... because these peripheral nerve cells can be extremely long ... a lot of distance for a molecular distress signal to ... cell,s nucleus. Scientists have believed this process to be ...
Cached Biology News:Report: Captive lion reintroduction programs in Africa operate under 'conservation myth' 2Report: Captive lion reintroduction programs in Africa operate under 'conservation myth' 3Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3
... Todays advanced protein cross-linking techniques are defined ... Dr. Shan S. Wong. This valuable hardcover ... schemes and current application references. More than ... protein cross-linking and conjugate preparation from ...
... active ingredient in Molecular Probes. SlowFadeAntifade ... to act as a free radical ... Our original SlowFade formulation (S-2828) was ... of fluorescein to almost zero (Figure ...
b6-2A12...
... kit are prepared with pure chemicals according ... Isolation Kit is designed to isolating intact ... easy way. One kit is consisted of ... mitochondria from 10 20 g tissue ...
Biology Products: